Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Q3 Revenues Drop to $6K as It Plans Cuts

NEW YORK (GenomeWeb News) – Compugen today reported that its third-quarter revenues declined to $6,000 from $90,000 year over year, as the firm plans to cut staff and reduce its expenses by 30 percent.
The Tel Aviv, Israel-based drug and biomarker discovery platform developer posted a net loss of $3.3 million, or $.12 per share, a 22 percent increase over a net loss of $2.7 million, or $.09 per share, for the third quarter of 2007.
Its R&D spending was flat year over year at $2.3 million, while its SG&A spending rose 9 percent to $1.2 million from $1.1 million.
Compugen finished the quarter with $10.3 million in cash, cash equivalents, short-term deposits, and marketable securities. It expects its cash usage for calendar 2009 will be roughly $8 million.
The company said yesterday that it intends to cut its expenses by around 30 percent and will lay off staffers, though it did not disclose how many.
Compugen also said that President and CEO Alex Kotzer will retire as of the end of the year and will be succeeded by Martin Gerstel, the company’s chairman.
Gerstel said in a release issued yesterday said that the firm intends to focus its internal R&D activities primarily on therapeutic peptides and monoclonal antibody drug targets. “In its biomarker and other programs, particularly in view of the current financial situation, the company intends to give priority to those activities pursued in collaboration with other companies,” he said in the statement.
Responding to investors’ concerns over the financial health of the company, Compugen issued a statement last week saying that it has sufficient cash on hand and marketable securities to run its business “well into 2010.” It also said that it has no intention of issuing equity at the firm’s current market value.
Compugen closed Wednesday at $.80 per share on the Nasdaq. It has a market cap of around $22.7 million.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.